2015
DOI: 10.1021/acs.chemrestox.5b00060
|View full text |Cite
|
Sign up to set email alerts
|

Catalytic Soman Scavenging by the Y337A/F338A Acetylcholinesterase Mutant Assisted with Novel Site-Directed Aldoximes

Abstract: Exposure to the nerve agent soman is difficult to treat due to the rapid dealkylation of soman-acetylcholinesterase (AChE) conjugate known as aging. Oxime antidotes commonly used to reactivate organophosphate inhibited AChE are ineffective against soman, while the efficacy of the recommended nerve agent bioscavenger butyrylcholinesterase is limited by strictly stoichiometric scavenging. To overcome this limitation, we tested ex vivo, in human blood, and in vivo, in soman exposed mice, the capacity of aging-res… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
22
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 41 publications
(23 citation statements)
references
References 39 publications
1
22
0
Order By: Relevance
“…and 280 mg/kg for i.v . application, classifying HI-6 as a reactivator of lower toxicity and confirming our previous results [18,29]. No toxicity symptoms were observed upon i.v.…”
Section: Resultssupporting
confidence: 91%
See 3 more Smart Citations
“…and 280 mg/kg for i.v . application, classifying HI-6 as a reactivator of lower toxicity and confirming our previous results [18,29]. No toxicity symptoms were observed upon i.v.…”
Section: Resultssupporting
confidence: 91%
“…Very slow aging makes it effective as a soman bioscavenger [18] and, as described here, VX toxicity and concentrations are also efficiently curtailed.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Current treatment relies on the use of anticholinergic drug atropine to reduce the effects of accumulating acetylcholine usually combined with oximes that reactivate phosphylated AChE (3)(4)(5). However, the potential of the oximes used in medical practice today, such as 2-PAM, HI-6, and obidoxime, is limited primarily due to the very specific properties of each of the enzyme-OP conjugates (6)(7)(8)(9).…”
mentioning
confidence: 99%